Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

gastrointestinal therapeutics

EU flag

CHMP backs Europe’s first allogeneic stem cell therapy

Takeda has ex-US rights to the Crohn's disease treatment from biotech TiGenix

dengue fever mosquito

Sanofi confirms suspected safety issue with dengue vaccine

As rival Takeda conduct phase II testing for its own dengue vaccine candidate

J&J launches digital skincare challenge

Seeks start-ups focused on tackling areas such as skin health adherence treatment

EU flag

Janssen’s Tremfya cleared for European use

EC approves the medicine to treat adults with plaque psoriasis

- PMLiVE

EC expands Janssen’s prostate cancer drug reach

Zytiga plus predinson/prednisolone will now treat mHSPC patients

- PMLiVE

GSK’s ViiV gets US okay for two-drug HIV regimen

Juluca is a combination of ViiV’s Tivicay and Janssen’s Edurant

- PMLiVE

Takeda Italia takes home digital innovation prize at Le Fonti Awards 2017

The pharmaceutical company wins award for its MyHospitalHub project

- PMLiVE

Lucid picks up rare disease and orphan drugs trophy at PMEA 2017

Judges praised the AbbVie project for its impressive reach

- PMLiVE

AbbVie named PMEA 2017 Company of the Year

Sees off strong competition from Amgen and Sanofi

- PMLiVE

Boehringer claims EU okay for Humira biosimilar

But won’t launch before expiration of the respective SPC for adalimumab in October 2018

- PMLiVE

Boehringer builds evidence base for its Humira biosimilar

Cyltezo shows clinical equivalence to AbbVie's blockbuster in a late-stage trial

dengue fever mosquito

Takeda dengue vaccine data looks good as it chases Sanofi

TAK-003 achieved a 71% reduction in developing the virus compared to placebo

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links